"Alendronate" - Books

Result Filters

Results: 1 to 20 of 132 books (847 items)

<< First< Prev

Page of 7

Next >Last >>

Select item 26591821.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 44036682.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2026 Jan-.

Top results in this book Table of Contents

Select item 34012943.

Endotext [Internet].

Feingold KR, Adler RA, Ahmed SF, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

Select item 53872444.

Assessing a 12-month course of oral alendronate for adults with avascular necrosis of the hip: MANTIS RCT with internal pilot.

Glyn-Jones S, Javaid MK, Beard D, et al.

Southampton (UK): National Institute for Health and Care Research; 2022 Oct. (Health Technology Assessment, No. 26.43.)

Top results in this book Table of Contents

Select item 55008545.

Romosozumab (Evenity): CADTH Reimbursement Review: Therapeutic area: Osteoporosis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jan.

Top results in this book Table of Contents

Select item 47870426.

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review [Internet].

Fink HA, MacDonald R, Forte ML, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Apr. (Comparative Effectiveness Review, No. 218.)

Top results in this book Table of Contents

Select item 57278647.

Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force [Internet].

Kahwati LC, Kistler CE, Booth G, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2025 Jan. (Evidence Synthesis, No. 238.)

Top results in this book Table of Contents

Select item 55428328.

Therapeutics Letter.

Perry T, editor.

Vancouver (BC): Therapeutic Initiatives; 1994-.

Top results in this book Table of Contents

Select item 50037369.

$Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.$

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

Davis S, Simpson E, Hamilton J, et al.

Southampton (UK): NIHR Journals Library; 2020 Jun. (Health Technology Assessment, No. 24.29.)

Top results in this book Table of Contents

Select item 226913610.

Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet].

Nelson HD, Haney EM, Chou R, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. (Evidence Syntheses, No. 77.)

Top results in this book Table of Contents

Select item 336759811.

$Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.$

Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.

Burch J, Rice S, Yang H, et al.

Southampton (UK): NIHR Journals Library; 2014 Feb. (Health Technology Assessment, No. 18.11.)

Top results in this book Table of Contents

Select item 433457012.

$A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.$

A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

Davis S, Martyn-St James M, Sanderson J, et al.

Southampton (UK): NIHR Journals Library; 2016 Oct. (Health Technology Assessment, No. 20.78.)

Top results in this book Table of Contents

Select item 421637613.

Denosumab (Prolia): Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture; or Who Have Failed or are Intolerant to Other Available Osteoporosis Therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Oct.

Top results in this book Table of Contents

Select item 485381614.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 547996015.

Bisphosphonates, teriparatide and deno-sumab for the treatment of postmenopausal osteoporosis: IQWiG Reports – Commission No. A19-10 [Internet].

Institute for Quality and Efficiency in Health Care (IQWiG).

Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2023 Jun 28.

Top results in this book Table of Contents

Select item 518116816.

$Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.$

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Robinson DE, Ali MS, Strauss VY, et al.

Southampton (UK): NIHR Journals Library; 2021 Mar. (Health Technology Assessment, No. 25.17.)

Top results in this book Table of Contents

Select item 256931017.

NIHR Health Technology Assessment programme: Executive Summaries.

Southampton (UK): NIHR Journals Library; 2003-.

Top results in this book Table of Contents

Select item 432507018.

Multimorbidity: Assessment, Prioritisation and Management of Care for People with Commonly Occurring Multimorbidity.

National Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 Sep. (NICE Guideline, No. 56.)

Top results in this book Table of Contents

Select item 557811219.

$The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.$

The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.

Guthrie B, Rogers G, Livingstone S, et al.

Southampton (UK): National Institute for Health and Care Research; 2024 Feb. (Health and Social Care Delivery Research, No. 12.04.)

Top results in this book Table of Contents

Select item 437649820.

Cerebral palsy in under 25s: assessment and management.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2017 Jan. (NICE Guideline, No. 62.)

Top results in this book Table of Contents

<< First< Prev

Page of 7

Next >Last >>

Supplemental Content

Images search in Bookshelf

Figure 4.

The effect of alendronate on bone mineral density in primary hyperparathyroidism. With alendronate, bone mineral density increases significantly after 1 year, while the placebo group shows no change until it is crossed over to alendronate in year 2. (Modified from reference Khan AA, Bilezikian JP, Kung AWC, et al: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-3325).

Primary Hyperparathyroidism.

Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
FIGURE 4

Cochrane risk-of-bias summary across non-bisphosphonate vs. bisphosphonate studies. ?, Unclear-risk of bias; +, low-risk of bias; –, high-risk of bias; blank cells, not a study outcome. ARCH, Active-controlled fracture study in postmenopausal women with osteoporosis at high risk; DAPS, Denosumab Adherence Preference Satisfaction; DECIDE, Determining Efficacy: Comparison of Initiating Denosumab versus alEndronate; EFFECT, EFficacy of Fosamax versus Evista Comparison Trial; EVA, EVista Alendronate comparison; FACT, Forteo Alendronate Comparator Trial; STAND, Study of Transitioning from Alendronate to Denosumab; VERO, VERtebral fracture treatment comparisons in Osteoporotic women.

Assessment of clinical effectiveness.

Davis S, Simpson E, Hamilton J, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2020 Jun.
Figure 15Musculoskeletal adverse events in trials of alendronate versus placebo

Results.

Crandall CJ, Newberry SJ, Diamant A, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar.
Figure 11Reflux and esophageal adverse events in trials of alendronate versus placebo

Results.

Crandall CJ, Newberry SJ, Diamant A, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar.